Trump Announces Deal to Drop Obesity Drug Prices to as Little as $149 a Month

President Trump announced a deal with drug manufacturers Novo Nordisk and Eli Lilly to reduce the monthly cost of popular obesity drugs to as low as $149. This agreement aims to increase access to medications like Wegovy and Zepbound for patients covered by Medicare and Medicaid, as well as those paying out-of-pocket. The lowest price point of $149 per month will apply to the lowest dosage forms of these drugs, making them available directly from manufacturers to self-paying individuals. For the injectable forms, such as Wegovy and Zepbound, the average out-of-pocket cost for self-paying Americans is expected to be around $350 per month initially, with a projected decrease to $245 over the next two years. While these measures are inten... download the app to read more